Skip to the page

Data / Form D filings / Urica Therapeutics, Inc.

Urica Therapeutics, Inc.: Form D filing

Urica Therapeutics, Inc., a biotechnology company in Bay Harbor Islands, FL, filed a Form D with the SEC in 2023. The latest, on January 5, 2023, reports $2.5 million sold of a $5 million offering to 26 investors.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
1111 KANE CONCOURSE, SUITE 301, Bay Harbor Islands, FL, 33154
Phone
(781) 652-4500
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Delaware
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
1959861

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Jan 5, 2023New notice$5,000,000$2,533,350$2,466,65026Dec 27, 2022sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Raymond S. ZhengExecutive Officer, Director
Jay D Kranzler, M.D., Ph.D.Executive Officer, Director
Michael S. WeissDirector
Vibeke S. Strand, M.D.Director
Lindsay A. Rosenwald, M.D.Director

Other biotechnology companies in Florida that filed recently

Every Form D from the week of Jan 2, 2023 · All recent filings in Florida · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what Urica Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.